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Abstract
Background
The World Health Organisation previously recommended routine screening in school-aged
children in countries with a high prevalence of rheumatic heart disease (RHD); however, it is
unclear if screening-detected (latent) valve disease will inevitably evolve to a pathological
lesion. Understanding the natural history of latent RHD is essential prior to recommendation
of screening in endemic areas. Studies documenting the progression of latent RHD have
had contrasting conclusions about the pathogenicity of latent valvular lesions. This review
provides estimates of rates of progression of latent RHD.
Methods and findings
In this systematic review and meta-analysis, we searched EMBASE, MEDLINE, Global
Index Medicus, Africa Wide, Cochrane Database of Systematic Reviews and Global Health
Database for studies published before April 30, 2019. Study data were extracted from all
studies which reported follow-up data on progression of latent valve lesions. Studies with
control cohorts were used to calculate comparative prevalence ratios. This study is regis-
tered with PROSPERO, number CRD42019119427. We identified 12 studies reporting fol-
low-up data on latent RHD for 950 people in 9 countries. The estimated pooled prevalence
rate for progression per year of latent RHD was 5%/year (95% CI 2–8). Eight studies
reported on the progression of borderline latent RHD with an estimated pooled prevalence
of 2%/year (95% CI 0–4). Three studies included control groups. There was a significant
increase in the risk of progression of valvular disease in the latent group compared with con-
trols (RR = 3.57 (95%CI = 1.65–7.70, P = 0.001). The overall risk of bias was low. Given
most studies included penicillin administration we were unable to document the natural his-
tory of latent RHD. Furthermore, we were unable to perform a sensitivity analysis to
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determine the effect of administering penicillin prophylaxis on progression of valve disease
given prescription of penicillin was not standardised.
Conclusion
Latent RHD has a slow rate of progression but it is significantly higher compared to controls,
with definite latent RHD having a higher rate of progression compared with borderline latent
disease. There are a massive number of individuals at risk for RHD in the developing world
as well as logistical challenges of screening and delivering penicillin prophylaxis. The low
rate of progression from untargeted screening may be an important consideration in
resource-constrained environments.
Introduction
While virtually eradicated from developed countries, rheumatic heart disease (RHD) causes
significant morbidity and mortality in low-income and middle-income countries as well as in
disadvantaged indigenous populations in developed nations. [1, 2] In contrast to the relative
neglect of this condition in past decades, [3] the availability of echocardiography-based screen-
ing has piqued the interest of researchers and policy makers in determining the global burden
of RHD. [1] Systematic screening with echocardiography has uncovered a high prevalence of
latent RHD compared with estimates based on clinically manifest disease. [4]
In response to the number of screening studies in asymptomatic individuals, the World
Heart Federation published guidelines to enable rapid detection of RHD in patients without a
history of ARF. [5] The three echocardiographic categories: ‘definite RHD’, ‘borderline RHD’,
and ‘normal’ provide a standardised template for screening. The World Health Organization
previously advocated for screening for RHD in endemic countries [6]. However, it is unclear
whether screening is a worthwhile exercise outside of prevalence estimation, given the natural
history of screening-detected definite and borderline RHD (together, termed latent RHD) is
unknown, [7] especially in mild cases. Echocardiography-based screening is more effective than
clinical screening [4] but it is also more expensive and logistically more challenging. Further-
more, the sequelae of screening are far from inconsequential with the current Australian guide-
lines recommending administration of intramuscular penicillin every 28 days for 5 years
following diagnosis of RHD or until age 21–40 years, depending on the severity of the lesion. [8]
Studies reporting follow-up data in patients with latent RHD have had conflicting results
[9] with some reporting predominantly stability and improvement [10–13] and others show-
ing heterogenous outcomes with significant progression, development of Definite RHD, ARF
and even death [14–18]. While the optimal approach of ascertaining the balance between bene-
fits and harms of penicillin administration in latent RHD is a randomised controlled trial,
there have been none so far. Given one of the fundamental requirements in evaluating a
screening test is to determine whether early pathologic changes are progressive, [19] we aimed
to systematically review and synthesise studies which report on the progression of latent valvu-
lar lesions. There have been two previously published meta-analyses examining the prevalence
of rheumatic heart disease is endemic countries, [7] [20] including one with a section on pro-
gression of latent RHD. [20] Our search was conducted approximately 1.5 years later and
includes additional cohorts. [12, 21, 22] We also present an annualised rate of progression of
latent and borderline RHD and comparison with controls. The primary outcome of this study
was to determine the pooled prevalence of progression of latent RHD. The secondary
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outcomes were to pool data on subsequent diagnosis of ARF, valve disease requiring interven-
tion, heart failure diagnoses, all-cause mortality and adherence to penicillin if prescribed.
Methods
Search strategy and selection criteria
A systematic review and meta-analysis were performed. We searched Medline, Embase, Global
Index Medicus (which includes Latin America and the Caribbean database LILACS as well as
World Health Organisation Library Information System WHOLIS), Global Health Database,
African Journals Online, and the Cochrane Database of Systematic Reviews on 30 April 2019,
for screening studies on RHD with neither language nor date restriction. A sample search
strategy is shown in S1 Appendix. Additionally, a manual search of all eligible articles’ refer-
ence lists, articles citing eligible articles as well as relevant review articles was carried out in
order to identify any additional literature.
We included all primary observational studies assessing the outcomes of latent RHD in
humans in countries classified as having a high/endemic incidence of RHD or specific popula-
tions with a high incidence of RHD in Western nations. Eligible studies had a cohort or case-
control design. We included studies in which outcomes have been reported for screened-nega-
tive and screened-positive cases and also those which report only the results of screened-posi-
tive patients.
Once the searches were completed, the software programmes Endnote (Clarivate Analytics,
Philadelphia, United States) and Covidence (Covidence, Melbourne, Australia) were used to
conduct the de-duplication of citations and for the screening process. Two authors (SJG and
ES) screened all titles and abstracts, reviewed full-text articles, and assessed their eligibility for
inclusion. Disagreements were resolved by discussion and a final decision was reached after
agreement between the reviewers.
Data extraction
All data were independently extracted by two reviewers (SJG and ES). Discrepancies were
resolved by mutual consensus. We extracted basic demographic data (country of study, age
and sex), echocardiographic criteria used, prescription of and adherence to secondary penicil-
lin prophylaxis as well as the prevalence of latent RHD. For studies using the 2012 WHF echo-
cardiographic criteria, prevalence of latent RHD was further divided into prevalence of
definite and borderline disease. We extracted length of follow up for each study and summary
estimates for percent of valve lesions which remained stable, regressed and progressed. Studies
with control groups using 2012 WHF criteria were used to calculate a pooled risk ratio of pro-
gression of latent RHD in screening positive cases compared with controls. The study quality
was assessed as part of the data extraction strategy by two reviewers (SJG and ES) with the
Standardised Risk of Bias Tool [23] designed to assess bias in population-based prevalence
studies. Items were rated as either low risk or high risk. All items rated as low risk were added
to calculate an overall score whereby a higher score indicated stronger methodology and a
lower risk of bias.
Statistical analysis
Given we were not evaluating the effect of an intervention, we dealt with progression as a pro-
portion and therefore it was appropriate to perform a meta-analysis of prevalence. We com-
bined the extracted prevalence and risk ratio data in a random-effects meta-analysis in Stata
version 15.1 (StataCorp, College Station, United States) with the metan [24] command. We
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estimated heterogeneity using the I2 statistic which we interpreted as low (25%), moderate
(50%) or high (75%). [25]
We performed sub-group analysis on pre and post 2012 WHF criteria. We performed a sen-
sitivity analysis on progression of valvular disease in borderline cases by removing 4 studies
which did not report on the progression of borderline RHD. Three studies were not included
in the analysis of the primary endpoint because they did not report on the progression of defi-
nite cases or only followed up borderline cases [11], [14], [12] All three were included in the
sensitivity analysis for progression of borderline cases.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data inter-
pretation, or writing of the report. SJG, AJT, THM and ES had full access to all the data in the
study and had final responsibility for the decision to submit for publication.
Deviation from the protocol
As most of our studies did not have a control group we used the standardised Risk of Bias Tool
which specifically assesses the risk of bias in prevalence studies. [23] Given the small number
of comparative studies uncovered in our search we were unable to generate a meaningful fun-
nel plot to assess for publication bias. [26] The planned subgroup analyses on patients by age,
type of echocardiographic abnormalities and adherence to penicillin if prescribed was not per-
formed due to lack of information in the studies. [27]
Results
We identified 3244 publications, 17 of which were potentially eligible (Fig 1). Twelve articles
describing 12 populations in 9 countries met the inclusion criteria and were included in the
systematic review and meta-analysis. Among the populations, 5 were from Africa, 4 from Oce-
ania, two from Asia and one from Latin America. The median age of the study population at
follow up, as reported in 7 studies, was 12.2 years (IQR 10.8–18), and the median percentage
of female subjects, as reported in 10 studies, was 59.3% (IQR 55–66) (Table 1).
The progression of latent RHD was reported in 9 studies and was 11% (95% CI 6–16) in
total, 6% (95% CI 1–11%) using non-WHF criteria and 15% (11–20) using the 2012 WHF crite-
ria (Fig 2) for the entire cohort over the duration of the study (follow up range 5.7–90 months).
The heterogeneity of reported prevalence was high between all studies (I2 = 84.5%, P<0.001).
Given there was a linear correlation between length of follow-up and progression of latent
RHD throughout duration of study (R(s) = 0.72, P =<0.001, weighted for sample size, Fig 3)
we estimated an annualised progression rate for latent RHD. The progression of latent RHD
per year was 5% (95% CI 2–8) per year in total, 6% (95% CI 0–12) using the non-WHF criteria
and 5% (95% CI 3–7) using the 2012 WHF criteria (Fig 4). The heterogeneity of reported prev-
alence was high between studies (I2 = 75.0%, P =<0.001).
The progression of borderline RHD was reported in 8 studies and was 13% (95% CI 7–18)
with a moderate heterogeneity of reported progression between all (I2 = 64.9%, P = 0.006) (Fig
5). The progression of borderline RHD per year was 2% (95% CI 0–4) with a low heterogeneity
of reported progression between all (I2 = 15.8%, P = 0.31) (Fig 6).
Risk ratio of progression of RHD
Three studies using the 2012 WHF echocardiographic criteria included control groups which
allowed us to calculate a pooled risk ratio for progression of latent RHD compared to controls.
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The risk ratio for progression of valvular lesions in those with latent RHD compared to con-
trols was 3.57 (95%CI = 1.65–7.70, P = 0.001) (Fig 7).
The rate of regression of latent RHD was reported in 9 studies and was 37% (95% CI 31–43)
in total for the duration of the study (Fig 8). The heterogeneity of reported prevalence was
moderate between all studies (I2 = 50.7%, P = 0.032). There was a linear correlation between
length of follow-up and regression of latent RHD throughout duration of study (R(s) = 0.45,
P =<0.001, weighted for sample size). We estimated the annualised regression rate for latent
RHD per year to be 15% (95% CI 10–20) with a moderate heterogeneity between studies (I2 =
70.0%, P = 0.001) (Fig 9).
Secondary outcomes
We were not able to perform meta-analysis of secondary outcomes due to lack of data and
therefore present a narrative review of pre-specified secondary outcomes.
Subsequent diagnosis of ARF. In Beaton et al’s 2014 study 2 children developed ARF
during the study period. One, a 10-year-old girl was in the borderline group and was not
receiving penicillin prophylaxis. The second, an 11-year-old boy, had received a diagnosis of
definite RHD and was prescribed monthly penicillin to which he described 100% adherence.
Mirabel et al reported an incidence of ARF of 10.28/1000/year. Remond et al reported 9 epi-
sodes of ARF during the follow up period. Beaton et al’s 2017 study and Saxena et al’s study
both reported no cases of ARF during the follow up period.
Fig 1. PRISMA [28] flow diagram for systematic review.
https://doi.org/10.1371/journal.pone.0234196.g001
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Valve disease requiring intervention. Four studies reported on this outcome. Zuhlke
et al described a 22-year-old girl who was HIV positive with borderline RHD at screening who
had severe MR at follow up with LV dilatation and reduced ejection fraction. She not been pre-
scribed penicillin. Engelman et al reported that 4 patients in their cohort required valvular sur-
gery. Beaton et al’s 2017 study and Mirabel et al’s study reported that there were no cases
requiring valvular intervention in the follow up period.
Heart failure diagnoses. Three studies reported on this outcome. Zuhlke et al described a
16-year-old girl with definite RHD who presented in heart failure at 8 weeks of pregnancy. She
had been adherent to monthly benzylpenicillin. The second child with a diagnosis of ARF
described in Beaton et al’s 2014 study was hospitalised due to severe congestive cardiac failure
in the setting of ARF. Mirabel et al reported one episode of heart failure during the follow up
period.
All-cause mortality. There were 2 studies which reported on death in the follow up
period. Beaton et al’s 2017 study reported that 2 patients (9.5% of patients diagnosed with
Fig 2. Progression over duration of study of latent rheumatic heart disease divided by sub-group (pre-publication of 2012 WHF criteria and post publication of
2012 WHF criteria).
https://doi.org/10.1371/journal.pone.0234196.g002
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moderate/severe definite RHD) died. Mirabel et al reported no deaths. Engelman et al reported
that 2 RHD cases from their screening cohort (1.5%) died from severe RHD prior to receiving
a follow up echocardiogram.
Factors associated with progression. In this review heterogeneity was too high for a
meta-regression. Seven studies reported on factors associated with persistence or progression
of latent RHD. Beaton et al in their 2014 and 2017 studies study found that younger children
were at a higher risk of an unfavourable outcome whereas in Kotit et al’s study, it was reported
that older children exhibited higher rates of progression. Other risk factors for progression
were: a greater number of mitral valve morphologic changes, [17] [18] [22] a higher anti-strep-
tolysin O titre, [17] overcrowded living conditions, [32] pathological mitral regurgitation, [16]
more advanced disease category, [18] and female sex. [22] Engelman et al found that only lon-
ger follow up (>5 years) was associated with improvement in echocardiographic diagnosis
and Bertaina et al, who followed up borderline cases only, did not find any risk factors for
progression.
Risk of bias
A summary of the risk of bias of the included articles is provided in Table 2. Ten studies (83%)
were considered to be at low risk of bias, and 2 studies were considered to be moderate risk
Fig 3. Correlation between length of study and progression of latent RHD weighted by sample size.
https://doi.org/10.1371/journal.pone.0234196.g003
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(17%), one due to lack of standardised echocardiographic criteria [13] and one due to short
follow up time. [21] Furthermore, there were four studies [21] [13] [12] [10] which did not
report whether echocardiography reporters were blinded to the diagnosis in the original stud-
ies which has the potential to introduce significant bias.
Discussion and conclusion
This is the most contemporary systematic review and meta-analysis pooling all studies report-
ing on progression of latent RHD and the first study to calculate an annual rate of progression
for both latent definite and borderline RHD. We have also shown that latent RHD has a higher
rate of progression compared to controls although the rate of regression is also very high.
In order to justify a screening program it must provide substantial benefit to the target pop-
ulation and must identify a significant proportion of the people at risk of developing the
adverse outcome. [34] RHD is endemic throughout much of the developing world and
although many attempts have been made to simplify echocardiographic protocols, screening
all at risk individuals with echocardiography is a huge undertaking.
Fig 4. Latent rheumatic heart disease: Progression per year.
https://doi.org/10.1371/journal.pone.0234196.g004
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Although echocardiographic screening poses no physical risk for those with a false positive
result, it is not a harmless process. Echocardiographic screening may have detrimental effects,
specifically increased anxiety as well as a decrease in physical activity among those who receive
an abnormal screening result. [35] Furthermore if the goal of screening is to institute second-
ary penicillin prophylaxis, we must determine whether prophylactic penicillin can mitigate
progression in latent disease as it does in RHD diagnosed after clinically manifest ARF. [36–
40] Administration of intra-muscular penicillin to children must be rigorously justified given
it is painful [41] and causes significant trauma for the patient, parents and health care worker
[42] with reports of significant peri-procedural anxiety, needle phobia, and medical fear. [43]
Negative experiences, when experienced by large numbers of children and adolescents,
amount to large harms for a population. [34]
That is not to say that there are no positives of echocardiographic screening. Given the dev-
astating complications and high mortality rate of clinically diagnosed RHD, [44] screening
may identify patients who are likely to benefit from cardiac surgery prior to the development
of irreversible heart failure, infective endocarditis or stroke. [45]
While surgical intervention or prophylactic penicillin may not always be necessary, close
follow up may be warranted, especially in patients in groups shown to have a greater propen-
sity for progression. Although we were unable to perform a meta-regression, predictors for
progression were extremely heterogeneous and some studies did not find any significant
Fig 5. Progression over duration of study of borderline rheumatic heart disease.
https://doi.org/10.1371/journal.pone.0234196.g005
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predictors. [11, 15] We reported that the rates of progression in latent RHD are higher than
the rates of borderline disease, highlighting the greater pathogenicity of screen detected defi-
nite RHD compared with borderline disease.
Given the high rates of regression of latent RHD it is possible that some normal cases are
being included in these studies and this may contribute to the very low rate of progression and
lack of identifiable risk factors for progression in these patients. [46] A test to differentiate
changes that are benign from changes that represent early RHD pathology would be highly
desirable in this population. Ideally, a secondary test can be applied to screened-positive
patients that is sensitive and more specific than echocardiography. The alternative might be to
identify the subset of cases with latent disease at highest risk of progression, such as those with
definite RHD, or at least to identify those at a low enough risk of progression to safely withhold
penicillin prophylaxis.
Echocardiographic screening for RHD does satisfy some of the basic fundamentals of a
screening test given there is a significant burden of RHD with an initial latent stage which can
be detected by echocardiography which is a simple, accessible, and sensitive test. What remains
to be seen is if the early stages are treatable by penicillin, and if early intervention improves
prognosis in a cost-effective manner. [47] The “GOAL (GwokO Adunu pa Lutino) Trial:
Determining the Impact of Penicillin on Latent Rheumatic Heart Disease” will randomise
Fig 6. Borderline rheumatic heart disease: Progression per year.
https://doi.org/10.1371/journal.pone.0234196.g006
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children aged 5–17 with latent RHD and compare progression of valvular lesions in children
receiving penicillin prophylaxis and children not receiving penicillin prophylaxis. [48] This
essential trial will hopefully address the clinical equipoise that has developed regarding penicil-
lin administration in latent RHD.
The progression rates of latent disease shown in our study are extremely low especially
when compared to the rates of lesion regression. Furthermore, in most of the included studies,
even in lesions that progress, there were extremely low rates of heart failure, severe valvular
disease and death Latent definite RHD was shown to have a high complication rate (20% over
a median follow-up of 7 years) in another cohort but this was postulated to be a country spe-
cific finding and may have represented a high rate of “missed clinical disease”. [45] In low risk
groups, the value of screening may be small, therefore like all tests, echocardiographic screen-
ing for the purpose of prophylactic penicillin administration needs to be evaluated in the con-
text of pre-test probability. A randomised trial is the ideal way to solve this conundrum and
must demonstrate feasibility, cost effectiveness and an incremental value of screening prior to
its widespread implementation. [48]
Limitations
Four studies did not utilise the 2012 World Heart Federation guidelines (Table 1). The guide-
lines used by these studies are less specific compared with the 2012 WHF guidelines. [49] In
order to overcome this, we split the pooled analysis for the primary endpoint into pre and post
2012 WHF criteria. The studies utilising the 2012 WHF guidelines had a higher pooled rate of
progression (15%) compared with the studies using the less specific criteria (6%). We believe
Fig 7. Pooled risk ratio of progression of latent RHD vs controls.
https://doi.org/10.1371/journal.pone.0234196.g007
PLOS ONE Echocardiographic screening for latent RHD
PLOS ONE | https://doi.org/10.1371/journal.pone.0234196 June 4, 2020 13 / 20
this is likely due to the inclusion of more normal cases in the older studies. There were 2 stud-
ies which reported different grades of definite RHD. [15, 18] The results for the pooled risk
ratio of progression of latent RHD vs controls (Fig 7) should also be interpreted with caution
given the small number of studies with available control groups.
We were unable to analyse the different grades of latent definite RHD individually however
we believe that this is an important distinction which warrants further study. The prescription
of penicillin was not uniform in the studies (Table 1) and therefore we were unable to perform
a sensitivity analysis to determine the effect of administering penicillin prophylaxis on pro-
gression of valve disease. There was significant heterogeneity detected in many of our analyses.
We believe the most important reasons for this are variation in diagnostic criteria used across
studies, different follow up periods in each study and different practices in all the countries
involved. Finally, although the risk of bias in included studies was mostly low, all were preva-
lent cohort studies and therefore prone to certain inherent bias. [50]
Echocardiographic screening identifies a group of patients who are at a higher risk of pro-
gressive disease compared to the general community but it is not clear if the risk is high
enough to justify penicillin prophylaxis. Future research will focus of better ways of further
stratifying this increased-risk cohort.
Fig 8. Regression over duration of study of latent rheumatic heart disease.
https://doi.org/10.1371/journal.pone.0234196.g008
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Fig 9. Latent rheumatic heart disease: Progression per year.
https://doi.org/10.1371/journal.pone.0234196.g009
Table 2. Standardised risk of bias tool.
Paar,
2010
Bhaya,
2011
Saxena,
2011
Beaton,
2014
Re´mond,
2015
Mirabel,
2015
Zu¨hlke,
2016
Engelman,
2016
Bertaina,
2017
Beaton,
2017
Kotit,
2017
Sanyahumbi,
2019
Study Design Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
Prevalent
cohort
External
validity
Was the study’s
target
population a
close
representation
of the national
population in
relation to
relevant
variable?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was the
sampling frame
a true or close
representation
of the target
population?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
(Continued)
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Table 2. (Continued)
Paar,
2010
Bhaya,
2011
Saxena,
2011
Beaton,
2014
Re´mond,
2015
Mirabel,
2015
Zu¨hlke,
2016
Engelman,
2016
Bertaina,
2017
Beaton,
2017
Kotit,
2017
Sanyahumbi,
2019
Was some form
of random
selection used
to select the
sample, OR,
was a census
undertaken?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was the
likelihood of
non-response
bias minimal?
Yes Yes Yes No Yes Yes Yes Yes Yes No Yes Yes
Internal
validity
Were data
collected
directly from
the subjects (as
opposed to a
proxy)?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was an
acceptable case
definition used
in the study?
Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was the study
instrument that
measured the
parameter of
interest shown
to have
reliability and
validity?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was the same
mode of data
collection used
for all subjects?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was the length
of the shortest
prevalence
period for the
parameter of
interest
appropriate?
No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Were the
numerator (s)
and
denominator r
(s) for the
parameter of
interest
appropriate?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Score 9 9 10 9 10 10 10 10 10 10 10 10
Summary item
on the overall
risk of study
bias
Moderate Moderate Low Low Low Low Low Low Low Low Low Low
https://doi.org/10.1371/journal.pone.0234196.t002
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